Igc pharma's puerto rico calma trial site offers strategic opportunity in high-prevalence alzheimer's market

Potomac, md / access newswire / may 22, 2025 / igc pharma, inc. ("igc", or the "company") (nyse american:igc) today announced a clinical trial site at santa cruz behavioral in puerto rico for its calma phase 2 clinical trial, investigating igc-ad1 for agitation in alzheimer's disease. this strategic site directly addresses the significant impact of alzheimer's in the region.
IGC Ratings Summary
IGC Quant Ranking